Cost Effectiveness of Latest Recommendations for Group B Streptococci Screening in the United States

Obstet Gynecol. 2020 Aug;136(2):429. doi: 10.1097/AOG.0000000000004035.
No abstract available

Publication types

  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Humans
  • Mass Screening*
  • Streptococcus agalactiae*
  • United States